Latest papers

Increased urinary excretion of carnitine and acylcarnitine by mercuric chloride is reversed by 2,3-dimercapto-1-propanesulfonic acid in rats.

Iron overload, hematopoietic cell transplantation, and graft-versus-host disease.

Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a nationally representative managed-care population

Alpha and beta thalassemia.

The treatment of secondary hemochromatosis.

Oral iron chelation therapy with deferiprone in patients with Thalassemia Major.

Maternal-fetal lead poisoning from an old slug: 10-year follow-up.

Sequential antiviral and iron chelation treatment in a teenage boy with congenital anemia, chronic hepatitis C, and secondary hemosiderosis.

Proceedings of the 17th International Conference on Chelation (ICOC) for the Treatment of Thalassemia, Cancer and Other Diseases Related to Metal and Free Radical Imbalance and Toxicity. November 2007. Shenzhen, China.

Prospects for introducing deferiprone as potent pharmaceutical antioxidant.

Lead poisoning due to gunshot bullet in contact with cerebrospinal fluid: case report.

Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.

Association of secondary hyperparathyroidism with CKD progression, health care costs and survival in diabetic predialysis CKD patients.

[Effects of chelation therapy with succimer in young rabbits of moderate lead poisoning].

Iron overload: consequences, assessment, and monitoring.

A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.

Manganese and its role in Parkinson's disease: from transport to neuropathology.

Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions.

The proceedings of the 17th International Conference on Chelation: application of effective chelation therapies in iron loading and non iron loading conditions, and the gap in the prevention and treatment policies on thalassemia between developed and developing countries.

Overview of iron chelation therapy with desferrioxamine and deferiprone.